Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Sold by EAM Investors LLC

EAM Investors LLC cut its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 25.9% during the 4th quarter, Holdings Channel reports. The firm owned 95,019 shares of the company’s stock after selling 33,257 shares during the period. EAM Investors LLC’s holdings in Eton Pharmaceuticals were worth $1,266,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Jump Financial LLC purchased a new stake in Eton Pharmaceuticals in the 4th quarter valued at approximately $329,000. XTX Topco Ltd lifted its position in shares of Eton Pharmaceuticals by 29.6% in the fourth quarter. XTX Topco Ltd now owns 14,655 shares of the company’s stock valued at $195,000 after acquiring an additional 3,351 shares in the last quarter. Barclays PLC acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at $731,000. Raymond James Financial Inc. purchased a new stake in Eton Pharmaceuticals during the 4th quarter worth about $147,000. Finally, Renaissance Technologies LLC raised its stake in Eton Pharmaceuticals by 131.5% in the 4th quarter. Renaissance Technologies LLC now owns 193,100 shares of the company’s stock valued at $2,572,000 after purchasing an additional 109,700 shares during the last quarter. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Trading Down 0.8 %

ETON stock opened at $14.08 on Thursday. The stock has a 50-day moving average price of $14.31 and a two-hundred day moving average price of $12.55. The company has a market cap of $377.60 million, a PE ratio of -64.00 and a beta of 1.34. Eton Pharmaceuticals, Inc. has a 12-month low of $3.03 and a 12-month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Equities analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

ETON has been the subject of a number of recent research reports. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, B. Riley restated a “buy” rating and issued a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.